Accentia Biopharmaceuticals, Inc., a biotechnology company, primarily discovers, develops, and commercializes immunotherapies to treat autoimmune related diseases and cancer in the United States. The company develops Cyrevia as a system of care for various autoimmune diseases; BiovaxID as a personalized therapeutic cancer vaccine to treat non-Hodgkin’s lymphoma, follicular lymphoma, mantle cell lymphoma, and other B-cell cancers; and SinuNasal lavage system as a medical device for chronic sinusitis. It also manufactures and sells a range of cell culture systems used for the production cell culture products, including HF Primer, a cell culture system for producing small, research, and develop...
324 South Hyde Park Avenue
Tampa, FL 33606
Founded in 2002
Accentia Biopharmaceuticals, Inc. announced delayed 10-Q filing
Aug 15 13
On 08/15/2013, Accentia Biopharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Shapiro Haber & Urmy LLP and Liggio Benrubi PA Files Class Action Lawsuit Against Accentia Biopharmaceuticals, Inc. and Officers and Directors of Accentia and Biovest International, Inc
Jul 30 13
Shapiro Haber & Urmy LLP and Liggio Benrubi PA filed a class action on July 26, 2013 against Accentia Biopharmaceuticals, Inc. (ABPI) and certain officers and directors of Accentia and Biovest International, Inc., a majority-owned subsidiary of Accentia, for violations of federal securities laws. The case has been filed in the United States District Court for the Middle District of Florida and is entitled Hill v. Accentia Biopharmaceuticals, et al., C.A. No. 13-cv-01945. The Complaint alleges that the FDA informed Biovest that the results of a Phase III clinical trial for BiovaxID, a potential vaccine for the treatment of non-Hodgkin's lymphoma, did not support an application for approval of BiovaxID. Despite this information, Defendants made numerous statements in press releases and securities filings that gave the misleading impression that the trial results were statistically significant and that Biovest was on track to obtain FDA approval. The Complaint alleges that these misstatements and omissions by Defendants misrepresented and/or omitted material facts to the investing public, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act. The class action is brought on behalf of all persons and entities who purchased common stock of either Accentia or Biovest from July 26, 2008 through August 14, 2012.